16 November 2015 - According to the findings, there is an indication of major added benefit of nivolumab over the appropriate comparator therapy docetaxel for under-75-year-olds in relatively good general condition, and a hint of a non-quantifiable added benefit for over-75-year-olds in relatively good general condition. For patients in worse general condition, an added benefit is not proven due to a lack of study data.

For more details, go to: https://www.iqwig.de/en/press/press-releases/press-releases/nivolumab-in-non-small-cell-lung-cancer-indication-of-major-added-benefit-for-under-75-year-olds.7060.html